Skip to content

Observation on the Therapeutic Effect of Yijinjing Prescription Based on Jingjin Theory in the Treatment of Ankylosing Spondylitis

Observation on the Therapeutic Effect of Yijinjing Prescription Based on Jingjin Theory in the Treatment of Ankylosing Spondylitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002342
Enrollment
Unknown
Registered
2025-11-28
Start date
2025-11-04
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

axSpA/AS

Interventions

intervention group:After undergoing basic treatment (with no restrictions on medication use and combined medication), perform the Yigengjing prescription training for 12 weeks.
control group:Receive basic treatment (with no restrictions on medication use and combination therapy) and be required to maintain the original level of physical activity for 12 weeks

Sponsors

Beijing University of Chinese Medicine Dongzhimen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The participants selected for this study must meet all of the following inclusion criteria: 1) Age between 18 and 75 years old; 2) Gender is not restricted; 3) Meet the classification criteria for axial spondyloarthritis (SpA) recommended by the International Ankylosing Spondylitis Assessment Group in 2009. 4) Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP): 1.3 - 3.5; 5) No use of non-steroidal anti-inflammatory drugs within 2 weeks before enrollment; if using non-steroidal anti-inflammatory drugs, they must have been using them stably for 1 month before enrollment. 6) No use of biologics within 3 months before enrollment. If using biologics, they need to have been using them stably for 1 month before enrollment to be included; 7) No participation in any traditional Chinese medicine non-pharmacological trials within 4 weeks before enrollment; 8) Able to practice Yi Jin Jing for 3 months; 9) Voluntary to participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: The participants will not be eligible to participate in this trial if they have any of the following conditions: 1) Pregnant women, women preparing for pregnancy or those in lactation period; 2) Those who have had or currently have malignant tumors; 3) Those with acute or chronic infectious diseases; 4) Those diagnosed with other rheumatic immune diseases; 5) Patients with other known diseases that require special attention in the exercise rehabilitation program, such as patients with cardiovascular diseases or those with a high-risk assessment of cardiovascular conditions; patients with cervical vertebral bone bridges; patients who have undergone surgical treatment within the past 6 months; 6) Patients who have been regularly exercising (such as yoga, Tai Chi, Ba Duan Jin, etc., = 3 times/week, 20 minutes each time) in the past 3 months; patients who have used self-management applications for chronic diseases or received corresponding treatment before; 7)Those considered by the researchers not to meet the requirements for joining this clinical trial.

Design outcomes

Primary

MeasureTime frame
Ankylosing Spondylitis Disease Activity Score with C-reactive protein ;

Secondary

MeasureTime frame
Ankylosing Spondylitis Disease Activity Score with C-reactive protein;Assessment in Spondylarthritis International Society for 20 % improvement;Bath Ankylosing Spondylitis Disease Activity Index;Bath Ankylosing Spondylitis Functional Index;Bath Ankylosing Spondylitis Metrology Index;Medical Outcomes Study 36-Item Short-Form Health Survey;Complete blood count;erythrocyte sedimentation Rate;C-reactive protein;

Countries

China

Contacts

Public ContactWanghailong

Beijing University of Chinese Medicine Dongzhimen Hospital

wanghailong@bucm.edu.cn13021044721

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026